《Journal For Immunotherapy Of Cancer》重点专注发布Biochemistry, Genetics and Molecular Biology-Molecular Medicine领域的新研究，旨在促进和传播该领域相关的新技术和新知识。鼓励该领域研究者详细地发表他们的高质量实验研究和理论结果。根据网友分享的投稿经验，平均审稿速度为 18 Weeks 。该杂志创刊至今，在Biochemistry, Genetics and Molecular Biology-Molecular Medicine领域，影响力非凡，对来稿文章质量要求很高，稿件投稿过审难度很大，刊登文章的学术水平和编辑质量在同类杂志中均名列前茅。如果你想在该杂志上发表论文，你可以向编辑部提交文章，但文章必须具有重要意义并代表该领域专业的发展。我们欢迎广大同领域的研究者提交投稿。
| CiteScore | SJR | SNIP | CiteScore排名 | |||
|---|---|---|---|---|---|---|
| 17.7 | 3.728 | 1.645 | 学科类别 | 分区 | 排名 | 百分位 |
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Pharmacology
|
Q1 | 11/313 | 96% | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：MolecularMedicine
|
Q1 | 11/178 | 94% | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Oncology
|
Q1 | 25/404 | 93% | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：CancerResearch
|
Q1 | 18/230 | 92% | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：ImmunologyandAllergy
|
Q1 | 20/233 | 91% | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Immunology
|
Q1 | 23/236 | 90% | |||
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：IMMUNOLOGY | SCIE | Q1 | 12 / 181 | 93.6% |
| 学科：ONCOLOGY | SCIE | Q1 | 26 / 322 | 92.1% |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：IMMUNOLOGY | SCIE | Q1 | 14 / 181 | 92.54% |
| 学科：ONCOLOGY | SCIE | Q1 | 29 / 322 | 91.15% |
文章名称
引用次数
Cytokine release syndrome
246
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
176
Targeting adenosine for cancer immunotherapy
81
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
68
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
63
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
62
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
58
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
56
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
55
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after >= 1 year of follow-up: JAVELIN Merkel a phase 2 clinical trial
53
国家/地区
发文量
TUSA
2013
TGERMANY (FED REP GER)
244
TCHINA MAINLAND
243
TFrance
193
TEngland
186
TItaly
134
TCanada
124
TSwitzerland
116
TNetherlands
115
TSpain
98
